Arkowitz David has filed 16 insider transactions across 2 companies since February 2023.
Most recent transaction: a grant/award of 13500 shares of iBio, Inc. ($IBIO) on November 20, 2025.
Activity breakdown: 1 open-market purchase and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov. 20, 2025 | iBio, Inc. | $IBIO | Arkowitz David | Director | A | Stock Option (right to buy) | 13500 | $0.00 | 13,500.0000 | 52,981,000 | 9999.99% | 0.03% |
| Jan. 10, 2025 | iBio, Inc. | $IBIO | Arkowitz David | Director | P | Common Stock | 18382 | $2.72 | 18,382.0000 | 9,132,000 | 9999.99% | 0.20% |
| Nov. 21, 2024 | iBio, Inc. | $IBIO | Arkowitz David | Director | A | Stock Option (right to buy) | 12600 | $0.00 | 12,600.0000 | 8,633,000 | 9999.99% | 0.15% |
| Feb. 14, 2024 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | A | Stock Option (Right to Buy) | 287905 | $0.00 | 287,905.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2024 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | A | Restricted Stock Units | 35625 | $0.00 | 35,625.0000 | 0 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | M | Restricted Stock Units | 10625 | $0.00 | 31,875.0000 | 0 | 25.00% | 0.00% |
| Feb. 15, 2024 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | M | Common Stock | 10625 | $0.00 | 186,381.0000 | 0 | 6.05% | 0.00% |
| Feb. 16, 2024 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | S | Common Stock | 3939 | $1.08 | 182,442.0000 | 0 | 2.11% | 0.00% |
| Feb. 14, 2024 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | A | Stock Option (Right to Buy) | 213750 | $0.00 | 213,750.0000 | 0 | 9999.99% | 0.00% |
| Oct. 27, 2023 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | M | Common Stock | 13209 | $0.00 | 179,822.0000 | 0 | 7.93% | 0.00% |
| Oct. 30, 2023 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | S | Common Stock | 4066 | $1.35 | 175,756.0000 | 0 | 2.26% | 0.00% |
| April 27, 2023 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | A | Restricted Stock Units | 26418 | $0.00 | 26,418.0000 | 0 | 9999.99% | 0.00% |
| Oct. 27, 2023 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | M | Restricted Stock Units | 13209 | $0.00 | 13,209.0000 | 0 | 50.00% | 0.00% |
| April 27, 2023 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | A | Common stock | 42500 | $0.00 | 166,613.0000 | 0 | 34.24% | 0.00% |
| Feb. 3, 2023 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | A | Restricted Stock Units | 42500 | $0.00 | 42,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 3, 2023 | Seres Therapeutics, Inc. | $MCRB | Arkowitz David | Chief Financial Officer | A | Stock Option (Right to Buy) | 85000 | $0.00 | 85,000.0000 | 0 | 9999.99% | 0.00% |